Express Scripts Introduces Novel Formulary Built for Evolution of Drug Pricing
"Some manufacturers have already followed our lead to create a pathway to help close the 'gross-to-net bubble,' and give cash-paying patients immediate access to more affordable medicine in a way that will not destabilize the drug supply chain," said
Drug makers set drug prices, and can lower them at any time. However, immediate list price decreases for products already on the market can pose challenges for employers and health plans that already have underwritten plan offerings and benefit designs for upcoming years based on existing economics.
By introducing authorized alternative products, through a new or additional National Drug Code (NDC) with a lower list price, we can create a competitive dynamic more similar to a generic coming to market. Cash-paying patients can have immediate access to the lower-priced medication. Meanwhile, employers and health plans can choose which product to cover that is best for their plan and their members: the lower-priced option or the original brand, which may have a rebate.
Over time, plans, pharmacies and others in the supply chain can transition to a new pricing model and the drug maker could ultimately retire their high list price product.
National Preferred Flex Formulary
The National Preferred Flex Formulary is a comprehensive formulary that will mirror our industry leading National Preferred Formulary -- covering more than 3,800 brand and generic medications -- and will follow
- When a manufacturer launches a lower-cost authorized alternative to a branded medication currently on the market,
Express Scriptswill evaluate the product for placement on the National Preferred Flex Formulary.
- If appropriate, the authorized alternative product will be added to the Flex formulary with preferred or possibly non-preferred status. The innovator brand-name product, and potentially other products in the therapy class, then will be excluded from coverage.
- Members enrolled in the Flex formulary who have a high-deductible or co-insurance plan design can have immediate access to the lower-priced authorized alternative medication.
Branded innovator products will remain preferred or non-preferred on other formularies, including
Asegua Therapeutics' authorized alternatives for hepatitis C treatments
Epclusa®(Sofosbuvir/Velpatasvir) and Harvoni® (Ledipasvir/Sofosbuvir) will be the first authorized alternatives managed through the National Preferred Flex Formulary. Additional products will be added as more drug makers bring authorized alternatives products to market.
Our home base is
We believe healthcare can do more. We are Champions For BetterSM.
View original content to download multimedia:http://www.prnewswire.com/news-releases/express-scripts-introduces-novel-formulary-built-for-evolution-of-drug-pricing-300748584.html